Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EASE SBS 5: Glepaglutide in Short Bowel Syndrome-intestinal Failure
NCT07197944Phase 3Recruiting
- Sponsor
- Zealand Pharma
- Start
- Feb 2026
- Primary completion
- Oct 2028
- Modality
- Peptides
- Countries
- 14
01
Overview
A Phase 3 trial of glepaglutide in short bowel syndrome (SBS), sponsored by Zealand Pharma. Started Feb 2026; status: recruiting.
02
Drugs
glepaglutide
03
Conditions
short bowel syndrome (SBS)
Beyond the preview
Go deeper on NCT07197944.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07197944.